Pfizer tracks experimental Drug's path in healthy men

NCT ID NCT07127770

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study by Pfizer enrolled 9 healthy adult men to learn how the experimental drug PF-07104091 is absorbed, broken down, and eliminated. Participants took the drug by mouth and later received a tiny radioactive dose intravenously. The study measured how much of the drug appeared in urine, feces, and blood, providing key information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PF-07104091 (a cyclin-dependent kinase-2 inhibitor)
What this could lead to
If successful, this study will help researchers understand how PF-07104091 moves through the body, which is a necessary step before testing it as a potential treatment for diseases like cancer.
What could go wrong
This is a very early, small study in just 9 healthy men, so results may not apply to patients or predict how the drug works in disease. The study is complete, but no treatment benefit is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON

    Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.